8 completed, 4 active not recruiting, 3 unknown, 1 not yet recruiting. 8 Phase 2, 6 Not applicable, 2 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Early-Stage Breast Carcinoma: new trials by email Literature Review of Early-Stage Breast Carcinoma trials Research Report on Early-Stage Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers Stereotactic Radiation Therapy, Endocrine Therapy - Breast Cancer, Early-Stage Breast Carcinoma | Not applicable | Not yet recruiting | Renaissance Institute of Precision Oncology and Radiosurgery | 30 | 2027-01-01 | 2026-09-28 |
| Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors Dietary Intervention - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Not applicable | Withdrawn | City of Hope Medical Center | 2022-06-15 | 2022-06-09 | |
| Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors Anhydrous Enol-oxaloacetate, Questionnaire Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 18 | 2021-09-29 | 2025-07-15 |
| Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer Anastrozole, Letrozole - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 161 | 2020-04-28 | 2025-01-28 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration - Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma | Phase 2 / Phase 3 | Suspended | M.D. Anderson Cancer Center | 928 | 2017-03-06 | 2026-09-14 |
| Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) Educational Intervention, Laboratory Biomarker Analysis, Meditation Therapy - Cancer Survivor, Early-Stage Breast Carcinoma | Not applicable | Unknown | Jonsson Comprehensive Cancer Center | 96 | 2017-02-20 | 2022-07-21 |
| ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism ME-344, Bevacizumab, Normal saline - Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Early Phase 1 | Completed | Centro Nacional de Investigaciones Oncologicas CARLOS III | 40 | 2016-07-01 | 2019-07-23 |
| Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin, Palbociclib - Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor | Phase 2 | Active not recruiting | Thomas Hatschek | 10 | 2015-10-01 | 2020-07-07 |
| A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Abemaciclib, Loperamide, Anastrozole - Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Completed | Eli Lilly and Company | 224 | 2015-08-01 | 2020-06-17 |
| Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer Standard Radiation, Hypofractionation with SIB - Early-Stage Breast Carcinoma | Not applicable | Active not recruiting | University Hospital Schleswig-Holstein | 2324 | 2015-06-16 | 2024-03-21 |
| Circadian Thermal Sensing to Detect Breast Disease Cyrcadia CBR™ device placement for abnormality screening - Early-Stage Breast Carcinoma | Phase 1 / Phase 2 | Unknown | Cyrcadia Health | 173 | 2015-06-01 | 2019-01-03 |
| Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases Paclitaxel, Tamoxifen + Palbociclib, Aromatase Inhibitor + Palbociclib - Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor | Phase 2 | Active not recruiting | Thomas Hatschek | 181 | 2015-02-01 | 2021-08-03 |
| Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer docetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin - Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Thomas Hatschek | 202 | 2014-11-01 | 2020-08-13 |
| A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients Immediate Acupuncture Group, Delayed Acupuncture Group - Taxane-induced Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy (CIPN) | Not applicable | Completed | Dana-Farber Cancer Institute | 57 | 2014-06-01 | 2026-04-07 |
| Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer without preoperative access to lymphoscintigraphy findings - Early-Stage Breast Carcinoma | Not applicable | Completed | Kliniken Essen-Mitte | 1198 | 2014-05-01 | 2020-07-09 |
| PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional Early-Stage Breast Carcinoma | Completed | University College, London | 222 | 2014-03-01 | 2017-03-17 | |
| TARGeted Intraoperative radioTherapy (TARGIT) Registry Database Early-Stage Breast Carcinoma | Unknown | University College, London | 2000 | 2013-07-01 | 2019-10-02 |
Breast Neoplasms (18) · Breast Carcinoma In Situ (4) · Carcinoma, Intraductal, Noninfiltrating (1) · Depression (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (18) · Neoplasms (18) · Neoplasms by Site (18) · Skin Diseases (18) · Skin and Connective Tissue Diseases (18) · Carcinoma (4) · Carcinoma in Situ (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (1) · Behavior (1) · Behavioral Symptoms (1) · Neoplasms, Ductal, Lobular, and Medullary (1)
Anastrozole (4) · Letrozole (3) · Aromatase Inhibitors (2) · Goserelin (2) · Paclitaxel (2) · Tamoxifen (2) · exemestane (2) · palbociclib (2) · Ado-Trastuzumab Emtansine (1) · Bevacizumab (1) · Celecoxib (1) · Cyclophosphamide (1) · Diet Therapy (1) · Docetaxel (1) · Doxorubicin (1)
Thomas Hatschek (3) · Jonsson Comprehensive Cancer Center (2) · University College, London (2) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · City of Hope Medical Center (1) · Cyrcadia Health (1) · Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1) · Kliniken Essen-Mitte (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Renaissance Institute of Precision Oncology and Radiosurgery (1) · Roswell Park Cancer Institute (1) · University Hospital Schleswig-Holstein (1)
United States (9) · Germany (3) · Sweden (3) · Netherlands (2) · Spain (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Canada (1) · Italy (1) · Portugal (1) · South Korea (1) · Switzerland (1) · Taiwan (1)
Jonas Bergh, Professor (3) · Benjamin D Smith (1) · Jayant S Vaidya (1) · Johannes Holtschmidt, MD (1) · Joshua Ellenhorn, MD (1) · Mo Keshtgar, MB BS, FRCS (1) · Patricia A Ganz (1) · Patricia Ganz (1) · Raynald Samoa (1) · Shipra Gandhi (1) · Thomas Hatschek, Assoc Prof (1) · Thomas Hatschek, Assoc prof (1)
PMID 31042410, PMID 31465263, PMID 31615937, PMID 32297442, PMID 34165503, PMID 34406839, PMID 35076812, PMID 36130057, PMID 36216274, PMID 36449695, PMID 38175448, PMID 38917400, PMID 39132946, PMID 41951647
2014 (1), 2015 (1), P30CA015083 (1), P30CA033572 (1), P50CA116201 (1), R01CA200977 (1), UL1TR001412 (1)